Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase
mBio · 2024
DOI: 10.1128/mbio.01085-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Kevin E Ramos und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: Neuraminidase, Hemagglutinin Glycoproteins, Influenza Virus, Antibodies, Bispecific, Antibodies, Viral. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | National Institutes of Health (NIH), NIAID NIH HHS.
Abstract (Originalsprache)
Monoclonal antibodies (mAbs) are an attractive therapeutic platform for the prevention and treatment of influenza virus infection. There are two major glycoproteins on the influenza virion surface: hemagglutinin (HA), which is responsible for viral attachment and entry, and neuraminidase (NA), which mediates viral egress by enzymatically cleaving sialic acid to release budding particles from the host cell surface. Broadly neutralizing antibodies (bNAbs) that target the conserved HA central stalk region, such as CR9114, can inhibit both viral entry and egress. More recently, broadly binding mAbs that engage and inhibit the NA active site, such as 1G01, have been described to prevent viral egress. Here, we engineered bispecific antibodies (bsAbs) that combine the variable domains of CR9114 and 1G01 into a single molecule and evaluated if simultaneous targeting of two different glycoproteins improved antiviral properties in vitro and in vivo . Several CR9114/1G01 bsAbs were generated with various configurations of the two sets of the variable domains (“bsAb formats”). We found that combinations employing the addition of a single-chain variable fragment in the hinge region of an IgG scaffold had the best properties in terms of expression, stability, and binding. Further characterization of selected bsAbs showed potent neutralizing and egress-inhibiting activity. One such bsAb (“hSC_CR9114_1G01”) provided higher levels of prophylactic protection from mortality and morbidity upon challenge with H1N1 than either of the parental mAbs at low dosing (1 mg/kg). These results highlight the potential use of bsAbs that simultaneously target HA and NA as new influenza immunotherapeutics. IMPORTANCE Infection by the influenza virus remains a global health burden. The approaches utilized here to augment the activity of broadly protective influenza virus antibodies may lead to a new class of immunotherapies with enhanced activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA.
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Integrated BioTherapeutics, Inc., Rockville, Maryland, USA.
- Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Meagan McMahon, Florian Krammer, Jonathan R Lai
Förderung
- HHS | National Institutes of Health (NIH)
- NIAID NIH HHS
Zitieren
APA
Ramos, K. E., Okba, N. M. A., Tan, J., Bandawane, P., Meade, P. S., Loganathan, M., Francis, B., Shulenin, S., Holtsberg, F. W., Aman, M. J., McMahon, M., Krammer, F., & Lai, J. R. (2024). Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase. mBio. https://doi.org/10.1128/mbio.01085-24
Vancouver
Ramos KE, Okba NMA, Tan J, Bandawane P, Meade PS, Loganathan M, et al. Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase. mBio. 2024. doi:10.1128/mbio.01085-24
BibTeX
@article{Ramos2024,
author = {Ramos, Kevin E and Okba, Nisreen M A and Tan, Jessica and Bandawane, Pooja and Meade, Philip S and Loganathan, Madhumathi and Francis, Benjamin and Shulenin, Sergey and Holtsberg, Frederick W and Aman, M Javad and McMahon, Meagan and Krammer, Florian and Lai, Jonathan R},
title = {Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase},
journal = {mBio},
year = {2024},
doi = {10.1128/mbio.01085-24}
}
EUVIMED